TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00090025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil Plus Leucovorin
Description: 5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
Study: NCT02393794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Histone deacetylase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Histone deacetylase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Histone deacetylase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum compound
Study: NCT02680808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam with F901318
Description: Pharmacokinetics of midazolam with F901318
Study: NCT02110303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: oral, 90mg tablets, twice daily, 12 month duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: oral, 90mg tablets, twice daily, 12 month duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical to ticagrelor), twice daily, 12 month duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical to ticagrelor), twice daily, 12 month duration
Study: NCT00488644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 75 mcg by mouth (PO) Daily for 8 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: 15 mcg PO Daily for 8 Weeks
Study: NCT02547792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-BYW.10 (Low Dose) Oral Vaccine
Description: Enteric coated tablet for oral delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-BYW.10 (High Dose) Oral Vaccine
Description: Enteric coated tablet for oral delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Enteric coated tablet for oral delivery
Study: NCT03142009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergenerational culturally adapted curriculum
Description: Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week.
Study: NCT06325735

Intervention type: DIAGNOSTIC_TEST
Intervention: None intervention
Description: None intervention, observational study
Study: NCT05027659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
Study: NCT02017158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Sprouts
Description: The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
Study: NCT01994941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used.
Study: NCT04509336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orphenadrine
Description: 100 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
Study: NCT01921101

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intensive medical nutrition
Description: provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: participants will receive standard care for nutrition received from hospital admission to discharge
Study: NCT02508350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: determination of plasma concentration
Description: A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
Study: NCT02762942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
Study: NCT01346696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)
Study: NCT04180020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ID/LAB
Description: ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
Study: NCT04031846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa
Description: Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
Study: NCT02510664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Strengths Study
Description: The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments.
Study: NCT02393794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum compound
Study: NCT04597606

Intervention type: OTHER
Intervention: Exercise with spontaneous ventilation.
Description: Patients will perform 10 minutes, constant load, exercise in a cycloergometer. To set the load, a baseline incremental effort test will be performed previously (VISIT 1).~Then, in a separate day (VISIT 2), the subject will perform 10 minutes cycling at the 75% load of that determined as maximum in VISIT 1, at a constant rate of 30 to 35 pedal revolutions per minute, in spontaneous breathing, with low flow oxygen through conventional nasal cannula adjusted to achieve SpO2 between 92to 94%
Study: NCT02393794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Platinum compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monoclonal antibody, checkpoint inhibitor
Study: NCT04597606

Intervention type: DEVICE
Intervention: Exercise with NIV
Description: VISIT 2 Non invasive mask ventilation: parameters will be titrated during a free cycling period at the end of the spontaneous breathing exercise. Then, in a separate day (VISIT 3), with the same constant load, cycling cadence and under NIV, the patient will perform 10 min of cycling.

Intervention type: DEVICE
Intervention: Exercise with HFNC
Description: With constant flows of 50 lpm and with FiO2 adjusted according to SPO2, to obtain a constant saturation between 92 and 94%. The same pedaling load and frequency will be maintained, with similar variables collected.
Study: NCT03231527

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting (CABG)
Description: myocardial revascularization

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting (CABG)
Description: myocardial revascularization
Study: NCT03568500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Medicine System
Description: DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
Study: NCT04654416

Intervention type: DRUG
Intervention: Corticosteroid with or without colchicine
Description: We describe the clinical outcome of patients treated with corticosteroid and colchicine

Intervention type: DRUG
Intervention: Corticosteroid with or without colchicine
Description: We describe the clinical outcome of patients treated with corticosteroid and colchicine
Study: NCT03568500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Medicine System
Description: DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Medicine System
Description: DMS components: a CoE product consisting of an approved antipsychotic medicinal product co-encapsulated with Conformité Européenne (CE)-marked miniature ingestible event marker in tablet; a CE-marked compatible medical device (a Proteus Patch \[Disposable Wearable Sensor Version 5\]); proprietary medical software (a local and remote computing application).
Study: NCT04241861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (High-flow oxygen therapy)
Description: Noninvasive respiratory support respiratory support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (Helmet PSV)
Description: Noninvasive respiratory support respiratory support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory support (Helmet CPAP)
Description: Noninvasive respiratory support respiratory support
Study: NCT01535716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hemodynamic optimization strategy driven by the ECOM
Description: goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) \& cardiac index (CI).~goals:~* SVV \< 11%~* IC \> 2,2 ml/min/m²~During the anesthesia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard management strategy
Description: goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~* Diuresis \> 0,5ml/kg/h~* Blood pressure , PAM \> 65 mmHg~* Pulse pressure variation~* CVP 8 to 12 cmH20~* Visual aspect of the heart~* Overload signs During the anesthesia
Study: NCT04706468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Capsules taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Capsules taken orally
Study: NCT03568500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Dosage determined by the healthcare professionals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosage determined by the healthcare professionals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage determined by the healthcare professionals.
Study: NCT02827851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of autologous SVF
Study: NCT05465278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 18 months treatment with alirocumab
Study: NCT00588991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given orally
Study: NCT04636099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT angiography（CTA）
Description: The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
Study: NCT05797220

Intervention type: DRUG
Intervention: Botulinum Toxin Type A Injection [Botox]
Study: NCT03568500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Dosage determined by the healthcare professionals.
Study: NCT04706468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Capsules taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TG-1000
Description: Capsules taken orally
Study: NCT05710601

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Operative laparoscopies carried out according to the most recent national guidelines and following the good clinical practice of our operative unit.
Study: NCT01060982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
Study: NCT04310670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Invasive Brain Stimulation (NIBS)
Description: Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS).
Study: NCT02887976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoluMatrix™ Abiraterone Acetate
Description: SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
Study: NCT01821235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurontin® (gabapentin) batch A
Description: Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurontin® (gabapentin) batch B
Description: Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabasandoz® (gabapentin) batch A
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabasandoz® (gabapentin) batch B
Description: Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
Study: NCT05797220

Intervention type: DRUG
Intervention: Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel
Study: NCT04156191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.15%
Description: ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
Study: NCT02768961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines
Study: NCT04156191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.05%
Description: ARQ-151 cream 0.05% applied to atopic dermatitis lesions once a day for 28 days
Study: NCT01590433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Study: NCT02768961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ledipasvir
Description: Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines
Study: NCT01840267

Intervention type: DEVICE
Intervention: ultrasonographic measurement of optic nerve sheath diameter
Description: A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
Study: NCT01590433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Study: NCT01898507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes
Description: 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.